Pier Paolo Olimpieri Selected Research

Pier Paolo Olimpieri Research Topics

4	COVID-19 08/2023 - 01/2022
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2023 - 01/2020
2	Immunoglobulin Light-chain Amyloidosis 01/2022 - 01/2022
1	Atherosclerosis 11/2023
1	Homozygous Familial Hypercholesterolemia 11/2023
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 11/2023
1	Disease Progression 08/2023
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2023
1	Fibrosis (Cirrhosis) 01/2023
1	Venous Thromboembolism 01/2022
1	Atrial Fibrillation 01/2022
1	Blast Crisis (Blast Phase) 01/2022
1	Heart Failure 01/2022

2	ponatinibIBA 01/2023 - 01/2022
2	Tyrosine Kinase InhibitorsIBA 02/2021 - 01/2020
1	LDL CholesterolIBA 11/2023
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2023
1	SubtilisinIBA 11/2023
1	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 11/2023
1	PCSK9 InhibitorsIBA 11/2023
1	oxidized low density lipoproteinIBA 11/2023
1	alirocumabIBA 11/2023
1	evolocumabIBA 11/2023
1	LipidsIBA 11/2023
1	nirmatrelvirIBA 08/2023
1	Ritonavir (Norvir)FDA Link 08/2023
1	molnupiravirIBA 08/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	ibrutinibIBA 01/2023
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2022
1	Bortezomib (Velcade)FDA Link 01/2022
1	AnticoagulantsIBA 01/2022
1	Immunoglobulins (Immunoglobulin)IBA 01/2022
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2022
1	remdesivirIBA 01/2022

2	Therapeutics 11/2023 - 01/2022